Press Releases

 
Press Releases
  Date Title View
May 14, 2015
Net Loss Reduced by 38% and Operating Cash Burn Cut by 42% from First Quarter 2014 Outlook Improved for 2015 WALTHAM, Mass., May 14, 2015 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), the developer of the BGM Galectin-3® Test, today reported financial results for the first quarter of 2015. "We continue to prepare...
May 7, 2015
WALTHAM, Mass., May 7, 2015 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD) today announced that the company will host a conference call and webcast on Thursday, May 14, 2015 at 8:30 a.m. Eastern Time to discuss its Q1 2015 financial results before the market opens. Conference Call Details The conference call may be accessed by ...
Mar 31, 2015
WALTHAM, Mass., March 31, 2015 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), the developer of the BGM Galectin-3® Test, today reported that it has filed a 510(k) Premarket Notification with U.S. Food and Drug Administration (FDA) for regulatory clearance of an additional indication for the BGM Galectin-3 Test. The filing incorpo...
Mar 31, 2015
Net Loss Reduced by 49% and Operating Cash Burn Cut by 47% From 2013 First Automated Galectin-3 Testing Expected to Launch in U.S. in Mid-2015 WALTHAM, Mass., March 31, 2015 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), the developer of the BGM Galectin-3® Test, today reported financial results for the three months and y...
Mar 26, 2015
WALTHAM, Mass., March 26, 2015 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD) announced today the publication of a landmark study, in the Journal of the American College of Cardiology, reporting clinical outcome results of the BioImage Study.[1] The BioImage Study, sponsored by BG Medicine in collaboration with pharmaceutical and healthcare co...
Mar 24, 2015
WALTHAM, Mass., March 24, 2015 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD) today announced that the company will host a conference call and webcast on Tuesday, March 31, 2015 at 8:30 am Eastern Time to discuss its fiscal year 2014 financial results before the market opens. Conference Call Details The conference call may be ...
Mar 13, 2015
WALTHAM, Mass., March 13, 2015 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD) (the "Company"), the developer of the BGM Galectin-3® Test, today announced its receipt of a notice of non-compliance from the NASDAQ Listing Qualifications Staff (the "Staff") of The NASDAQ Stock Market LLC ("NASDAQ"). The notice indicated that, because the Com...
Feb 2, 2015
WALTHAM, Mass., Feb. 2, 2015 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), the developer of the BGM Galectin-3® Test, announced today its receipt of a favorable decision from the Listing Qualifications Department (the "Staff") of The NASDAQ Stock Market LLC ("NASDAQ"), which granted the Company's request for continued listing on NASDAQ,...
Nov 20, 2014
WALTHAM, Mass., Nov. 20, 2014 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), the developer of the BGM Galectin-3® Test, announced today that 17 abstracts reporting independent research that investigates galectin-3 testing in various cardiovascular diseases have been presented at the American Heart Association's 2014 Scientific Sessions a...
Nov 13, 2014
Net Loss Reduced by 35% and Operating Cash Burn Cut by 48% From Third Quarter 2013 Company Retains Investment Bank to Explore Strategic Alternatives WALTHAM, Mass., Nov. 13, 2014 (GLOBE NEWSWIRE) -- BGMedicine, Inc. (Nasdaq:BGMD), the developer of the BGM Galectin-3®Test, today reported financial results for the third quarter 2...
1
... NextLast
= add release to Briefcase